Dystonia - Pipeline Review, H2 2016

Date: October 19, 2016
Pages: 45
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: DAF3A558499EN
Leaflet:

Download PDF Leaflet

Dystonia - Pipeline Review, H2 2016
Dystonia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dystonia - Pipeline Review, H2 2016, provides an overview of the Dystonia (Central Nervous System) pipeline landscape.

Dystonia is a movement disorder that causes the muscles to contract and spasm involuntarily. The movements may be painful, and some individuals with dystonia may have a tremor or other neurologic features. Symptoms include involuntary muscle contractions that cause repetitive movements or distorted postures, stress, fatigue or anxiety and speech difficulties. Treatment includes anticholinergic and benzodiazepines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dystonia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dystonia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dystonia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dystonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively for Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively for Dystonia.

Dystonia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dystonia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dystonia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dystonia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dystonia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dystonia (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dystonia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dystonia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Dystonia Overview
Therapeutics Development
Pipeline Products for Dystonia - Overview
Pipeline Products for Dystonia - Comparative Analysis
Dystonia - Therapeutics under Development by Companies
Dystonia - Therapeutics under Investigation by Universities/Institutes
Dystonia - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Dystonia - Products under Development by Companies
Dystonia - Products under Investigation by Universities/Institutes
Dystonia - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Advicenne SA
EpiVax, Inc.
Ipsen S.A.
Revance Therapeutics, Inc.
Dystonia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abobotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipraglurant ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetrabenazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dystonia - Dormant Projects
Dystonia - Product Development Milestones
Featured News & Press Releases
Mar 05, 2016: Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology
Oct 29, 2015: Revance Reports Positive 6-Month Duration in BELMONT Study
Sep 29, 2015: Revance Therapeutics Initiates Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical Dystonia
Feb 26, 2007: Epivax Funded To Advance Research On A New, Improved “Botox”
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 45

LIST OF TABLES

Number of Products under Development for Dystonia, H2 2016
Number of Products under Development for Dystonia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Dystonia - Pipeline by Addex Therapeutics Ltd, H2 2016
Dystonia - Pipeline by Advicenne SA, H2 2016
Dystonia - Pipeline by EpiVax, Inc., H2 2016
Dystonia - Pipeline by Ipsen S.A., H2 2016
Dystonia - Pipeline by Revance Therapeutics, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Dystonia - Dormant Projects, H2 2016 39

LIST OF FIGURES

Number of Products under Development for Dystonia, H2 2016
Number of Products under Development for Dystonia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Dystonia - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 50 pages
Dengue - Pipeline Review, H2 2015 US$ 1,600.00 Jul, 2015 · 204 pages
rEVO Biologics, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Jul, 2015 · 24 pages

Ask Your Question

Dystonia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: